Navigation Links
Sidestepping cancer's chaperone
Date:10/18/2007

WORCESTER, Mass. Cancerous tumors are wildly unfavorable environments. Struggling for oxygen and nutrients while being bombarded by the bodys defense systems, tumor cells in fact require sophisticated adaptations to survive and grow. For decades, scientists have sought ways to circumvent these adaptations to destroy cancer. Now, researchers at the University of Massachusetts Medical School (UMMS), have defined a method to target and kill cancers chaperonea protein that promotes tumor cell stability and survivalwithout damaging healthy cells nearby.

In Regulation of Tumor Cell Mitochondrial Homeostasis by an Organelle-Specific Hsp90 Chaperone Network, published in the October 19 issue of Cell, Dario C. Altieri, MD, the Eleanor Eustis Farrington Chair in Cancer Research and professor and chair of cancer biology, and colleagues at UMMS, identify a new pathway by which cancer cells grow and surviveand provide a clear blueprint for the design and production of a novel class of anticancer agents aimed squarely at that pathway.

While previous research has demonstrated that a class of proteins known as molecular chaperones promote tumor cell survival, the specific way in which the proteins achieve this has not been well understood. And although inhibitors of a specific chaperone known as heat shock protein 90 (Hsp90) have been studied for the treatment of cancer, progress has been questionable. In this current research, Dr. Altieri and colleagues sought to both define the mechanism by which Hsp90 leads to tumor cell stability and survival, and understand why general suppression of Hsp90 has not been as successful in clinical trials.

Notably, they found a very abundant pool of Hsp90 (and its related molecule TRAP-1) in the mitochondria of tumor cells. Mitochondria are organelles that produce a cells energy, but also play a key role in cell death. Indeed, many current drugs and treatments work by damaging the mitochondria. Data obtained by Altieri and colleagues indicate that Hsp90 and TRAP-1 protect mitochondria in tumor cells from fulfilling their role in cell death. Significantly, the increased levels of Hsp90 and TRAP-1 were found only in the mitochondria of tumor cellsnot in those of normal cells.

We have identified this mitochondrial accumulation of Hsp90 and TRAP-1 as a critical adaptive mechanism that makes cancer cells less susceptible to the unfavorable environment of tumors, and to various anticancer agents, Altieri explained.

This new understanding of the sub-cellular location of Hsp90 and TRAP-1 in the mitochondria also answers the question as to why the current Hsp90 inhibitorswhich do not penetrate the mitochondriaare not as effective as hoped in the clinic. In this study, Altieri and colleagues synthesized a new compound, modifying an existing Hsp90 inhibitor so that it was able to reach the mitochondria. When the inhibitors were able to penetrate the mitochondria, they were able to eliminate the protective function of Hsp90, and induce massive tumor cell death. Notably, because this accumulation of Hsp90 and TRAP-1 only occurs in tumor cells, drugs conceived to target Hsp90 would largely spare normal cells, minimizing or even nullifying the dramatic side effects that plague many current cancer treatments.

This is an important discovery that opens the door to the design of a completely new class of anticancer agents, Altieri explained. It really turns the tables on a field that has been explored with only partial success. We can now take a class of drugs and make them better and more efficacious by engineering them to accumulate in the mitochondria.


'/>"/>

Contact: Kelly Bishop
kelly.bishop@umassmed.edu
508-856-2000
University of Massachusetts Medical School
Source:Eurekalert

Related biology news :

1. First-ever Compounds To Target Only Metastatic Cells Are Highly Effective Against Breast, Prostate, And Colon Cancers
2. Towards precise classification of cancers based on robust gene functional expression profiles
3. Epstein-Barr virus protein crucial to its role in blood cancers
4. Antiretroviral therapy may prevent excess risk of some cancers in people with HIV
5. Study reveals dramatic difference between breast cancers in US and Africa
6. Chemists synthesize molecule that helps body battle cancers, malaria
7. Major breakthrough in the treatment of cancers and infectious diseases
8. Study: Harmless virus kills some cancers
9. High-throughput oncogene mutation detection in human cancers by mass spectrometry-based genotyping
10. Most common lung cancers may begin in newly discovered cells
11. Change in gene may be underlying molecular defect in some colorectal cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2017)... , Feb. 25, 2017  Securus Technologies, ... technology solutions for public safety, investigation, corrections and ... Recidivism and Reentry. "Too often, too ... prisons and county jails are trying to tackle ... inmates and friends and family members. While significant steps ...
(Date:2/21/2017)... PORTLAND, Ore. , Feb. 22, 2017 ... Family of Companies (Avamere Health Services, Infinity Rehab, Signature ... research study that will apply the power of IBM ... living and health centers. By analyzing data streaming from ... insights into physical and environmental conditions, and obtain deeper ...
(Date:2/14/2017)... Feb. 14, 2017  Wake Forest Baptist Medical Center ... new chief executive officer (CEO). Freischlag joins the medical ... D. McConnell , M.D., who last year announced that ... Medical Center, after leading it since 2008.   ... of Wake Forest Baptist,s academic health system, which includes ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... , March 23, 2017  Northwest Biotherapeutics ... DCVax® personalized immune therapies for solid tumor cancers, ... $7.5 million financing it announced last Friday, March ... to several institutional investors securities totaling 28,843,692 shares, ... share, and 10,000,000 shares of Class C Warrants ...
(Date:3/23/2017)... 23, 2017 Kineta, Inc., a biotechnology ... therapies in immuno-oncology, today announced the discovery and ... compounds that activate interferon response factor 3 (IRF3) ... immune-mediated tumor regression in a murine colon carcinoma ... demonstrated complete tumor regression to initial drug treatment ...
(Date:3/23/2017)... New Orleans, La. (PRWEB) , ... March 23, ... ... of real-time, industrial monitoring solutions, today announced the hire of Dr. Sigmund “Sig” ... for APMT customer applications, strategic partnerships and joint development activities. , “Dr. Floyd’s ...
(Date:3/22/2017)... March 22, 2017 Good Start Genetics, a ... eclipsed the 130 million covered lives mark through its ... Texas . With newly signed contracts ... to enjoy strong payor acceptance based on the quality ... and genetic counseling, its industry-leading customer care and support ...
Breaking Biology Technology: